Drug companies have wagered billions on bispecific antibody drugs ever since one of them, ivonescimab, a PD-1 and vascular ...
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARK CITY, Utah — In this Healio Video Perspective from ...
Zacks Investment Research on MSN
Arcus, Bristol Myers team up to advance kidney cancer study
Arcus Biosciences RCUS announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMY to evaluate casdatifan in combination with PD L1/VEGF A bispecific immunomodulator.
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Dual PD-L1 and VEGF-A blockade with pumitamig plus chemotherapy yielded a 70% overall response rate and 100% disease control in evaluable first-line advanced NSCLC without actionable alterations.
4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results